Episode 5: Among the topics: Iron deficiency in heart failure – Cardiovascular management of patients undergoing non-cardiac surgery

Nov 24, 2022

Ask episode

Chapters

Transcript

Episode notes

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.

This episode covers:

Cardiology This Week: A concise summary of recent studies
The IRONMAN trial and the role of iron deficiency in heart failure
New ESC Guidelines on cardiovascular management of patients undergoing non-cardiac surgery
Statistics Made Easy: Part I

Host: Rick Grobbee Guests: Sigrun Halvorsen, Paul Kalra and Emma Svennberg

Want to watch that episode? Go to: https://esc365.escardio.org/event/758

Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

Stephan Achenbach, Rick Grobbee, Sigrun Halvorsen and Nicolle Kraenkel declared to have no potential conflict of interest to report.

Carlos Aguiar declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede.

Giuseppe Biondi-Zoccai declared to have potential conflicts of interest to report: Giuseppe Biondi-Zoccai has consulted for Balmed, Cardionovum, Crannmedical, Eukon, Innovheart, Guidotti, Meditrial, Microport, Opsens Medical, Replycare, Teleflex, and Terumo.

Davide Capodanno declared to have potential conflicts of interest to report: Sanofi, Daiichi Sankyo, Terumo, Medtronic, Chiesi.

Paul Kalra declared to have potential conflicts of interest to report: Research grants: Pharmacosmos. Consultancy and lectures honoraria: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Pfizer, Pharmacosmos, Servier, Vifor Pharma .

Emma Svennberg declared to have potential conflicts of interest to report: Institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer- Ingelheim, Johnson & Johnson, Merck Sharp & Dohme